Category Archives: Emerging Markets
By Ben Comer | Published: July 12, 2012
The IMS Institute’s annual report on global drug spending predicts a slight rebound in developed markets, despite historically low growth rates. In emerging markets, growth continues to be robust, but is it enough to balance the ongoing stagnancy in Europe and the US?
By Ben Comer | Published: May 21, 2012
Recognizing that traditional market forces – namely incentives related to intellectual property and a steady demand for products – have failed in developing countries, the World Health Organization (WHO) asked a member state-nominated group to come up with ways to fund R&D and pay for the treatment of neglected diseases in the world’s poorest nations. [...]
By Guest Blogger | Published: February 23, 2012
Publicis Healthcare Gobbles Up Another Asian Agency Publicis continues its expansion into Asia with today’s (Feb 20) announcement of its acquisition of U-Link Business Solutions (UBS), one of China’s leading agencies specializing in healthcare communications. As a part of Publicis Healthcare Communications Group, the agency will be renamed UBS Saatchi & Saatchi Health. “The Chinese healthcare market is [...]
By Reid Paul | Published: February 10, 2012
By Ben Comer | Published: November 22, 2011
Tiered pricing, or selling critical medicines to developing countries at a standardized discount price, can improve access in the short term, but arbitrary demographic groupings and misaligned incentives often stack the deck in favor of manufacturers, not patients.